Business
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
Nantes, France, March 10, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive Officer, effective immediately. Mr. Le Bozec had served as interim CEO since October 2, 2025. Following a thorough review of internal and external candidates and upon recommendation of the Nomination and Compensation Committee, the Board of Directors unanimously confirmed Marc Le Bozec's transition from
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"Nantes, France, March 10, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive Officer, effective immediately. Mr. Le Bozec had served as interim CEO since October 2, 2025.","length":294,"tagName":"p"},{"type":"text","content":"Following a thorough review of internal and external candidates and upon recommendation of the Nomination and Compensation Committee, the Board of Directors unanimously confirmed Marc Le Bozec's transition from interim to permanent CEO.","length":240,"tagName":"p"},{"type":"text","content":"Dr. Markus Cappel, Chairman of the Board of OSE Immunotherapeutics, commented:“I am thrilled to announce Marc’s permanent appointment as CEO. Since stepping into the interim role, Marc has demonstrated the strategic 'grit' and visionary leadership required to navigate the complexities of our sector. His deep understanding of our pipeline and his ability to unite the team behind a common mission have been exemplary. The Board is fully aligned with Marc’s vision to scale our current assets into commercial successes, and we are confident that his leadership will drive significant value for our shareholders and, most importantly, for the patients who depend on our innovation.”","length":690,"tagName":"p"},{"type":"text","content":"Marc Le Bozec, Chief Executive Officer of OSE Immunotherapeutics, added:“I am deeply honored and energized to lead OSE Immunotherapeutics at such a pivotal moment in our journey. We are at a transition point where our scientific excellence is meeting critical clinical and commercial milestones. My focus is clear: to accelerate our breakthrough therapies and ensure that our novel medicines reach the patients in need as quickly as possible. ...